Triptocallic acid A is primarily studied for its anti-inflammatory and immunomodulatory properties. It has shown potential in inhibiting key inflammatory pathways, making it a candidate for research in autoimmune diseases such as rheumatoid arthritis and lupus. The compound also exhibits antiviral activity, particularly against certain enveloped viruses, by interfering with viral entry into host cells. Due to its ability to modulate immune cell activity, it is being explored for use in organ transplantation to reduce graft rejection. Additionally, preliminary studies suggest anticancer effects by inducing apoptosis in specific tumor cell lines, though these findings are still in early stages. Its natural origin and bioactivity profile make it a valuable lead compound in developing new therapeutic agents.